Factual and Procedural Background
The plaintiff, E.R. Squibb & Sons Inc., filed a suit against the defendant, Curewel (India) Ltd., seeking a permanent injunction restraining the defendant from selling its product under the brand name "Curechlor" or any deceptively similar mark to the plaintiff's registered trade mark "Reclor" in relation to the pharmaceutical preparation Chloramphenicol. Along with the suit, the plaintiff moved an application under Order 39 Rules 1 and 2 and Section 151 of the Code of Civil Procedure for a temporary injunction until the suit's decision.
The plaintiff's pleaded facts include: sale of its product under the trade mark "Reclor" in India since 1971 through registered users (Karamchand Premchand Pvt. Ltd. and Sarabhai Chemicals Ltd.), transfer to Elscope Pvt. Ltd. from March 1, 1977; registration of the trade mark "Reclor" in India on May 4, 1966 for medicinal and pharmaceutical preparations; and discovery in October 1984 that the defendant was selling Chloramphenicol capsules under the name "Curechlor." The plaintiff alleged that "Curechlor" is deceptively similar (visually and phonetically) to "Reclor" and that druggists, chemists or nurses might mistakenly supply or administer "Curechlor" when "Reclor" is prescribed.
Procedurally, the matter before the court was the plaintiff's interlocutory application for an interim injunction. The judge heard submissions and evidence relevant to that application. The court dismissed the interlocutory application. The file records: Suit No. 2152/85; parties were directed to appear before the Deputy Registrar on March 18, 1986 for admission/denial of documents; the suit was listed before the Court on May 26, 1986 for framing of issues; and the court's order concludes "I.A. dismissed."
Legal Issues Presented
- Whether the adoption of the trade mark "Curechlor" by the defendant for its product containing Chloramphenicol amounts to infringement/passing off or otherwise to a deceptive similarity actionable in respect of pharmaceutical preparations.
- Whether the plaintiff demonstrated a prima facie case and a likelihood of ultimate success sufficient to justify a temporary (interlocutory) injunction restraining the defendant from using "Curechlor" pending trial.
Arguments of the Parties
Plaintiff's Arguments
- The plaintiff has been selling Chloramphenicol under the trade mark "Reclor" in India since 1971 and holds a registration for "Reclor" dated May 4, 1966 for medicinal and pharmaceutical preparations.
- The defendant adopted the mark "Curechlor" by adding "Cu" at the beginning and an "h" after the "c" of "Reclor," resulting in a mark visually and phonetically deceptively similar to "Reclor."
- There is a likelihood of confusion: druggists and chemists might supply "Curechlor" mistakenly when "Reclor" is prescribed; even trained nurses might be misled into giving "Curechlor" in place of "Reclor."
- The plaintiff placed two cash memos on record relating to sales of "Curechlor." The plaintiff's counsel cited authorities (e.g., Kemp & Co. Ltd. v. Cadilla Laboratories Pvt. Ltd.) in support of the contention that "Curechlor" is deceptively similar to "Reclor."
Defendant's Arguments
- The defendant relied on case law (including the Supreme Court decision in F. Hoffiman-La Roche v. Geoffrey Manners and various English and Indian authorities) to submit that the question of deceptive similarity must be assessed having regard to the class of goods involved; for medicinal preparations that are typically supplied on prescription, chances of confusion are remote.
- The defendant's trading style is Curewel (India) Ltd., and the defendant adopted the prefix "Cure" from its trading style and the element "chlor" from the drug "Chloramphenicol," which is a bona fide and common pharmaceutical naming practice.
- There was no allegation (or material placed on record) that the defendant acted dishonestly in adopting the mark "Curechlor" or that any specific instance of confusion had occurred; records (price list and cash memos) show prescription-based sale practices and multiple product names by the defendant beginning with "Cure," supporting bona fides.
Table of Precedents Cited
| Precedent |
Rule or Principle Cited For |
Application by the Court |
| F. Hoffiman-La Roche & Co. Ltd. v. Geoffrey Manners and Co. Private Ltd., AIR 1970 S.C. 2062 |
That the question of deceptive similarity must be decided on the basis of the class of goods to which the trademarks apply; for medicinal goods typically obtained on prescription, the likelihood of confusion is remote; in that case "Dropovit" was held not deceptively similar to "Protovit." |
The court adopted this principle and applied it to the present dispute, assessing deceptive similarity in the context of medicinal preparations dispensed on prescription. |
| Re: Bayer Products, Ltd.'s Application, (1947) 2 All E.R. 188 |
English authority relating to pharmaceutical preparations; cited among cases illustrating the approach to trademarks in pharmaceuticals. |
Cited by the defendant's counsel as part of a body of authorities supporting the view that assessment depends on class of goods; the court noted that these English decisions took a similar approach to Hoffmann-La Roche. |
| Geigy A.G v. Chelsea Drug and Chemical Company Ltd., (1966) RPC 64 |
English authority relating to pharmaceutical trademarks; referenced for approach to pharmaceutical cases. |
Referred to by defendant's counsel; the court recorded that such judgments align with the Hoffmann-La Roche principle and applied that contextual approach. |
| Indo-Pharma Pharmaceutical Works Pvt. Ltd. v. Farbenfabriken Bayer Ag., (1975) RPC 545 |
Authority on pharmaceutical trademark disputes; part of the group of cases cited to show consistent approach in pharmaceutical matters. |
Included among authorities relied on by defendant's counsel; court noted this line of cases supports the contextual test adopted from Hoffmann-La Roche. |
| Stadmed Pvt. Ltd., Calcutta v. Hind Chemicals, Kanpur, AIR 1965 Punjab 17 |
Indian case law referred to in the context of pharmaceutical trademark disputes. |
Referred to by the defendant's counsel as part of a series of decisions dealing with pharmaceutical preparations; court treated it as consistent with the Hoffmann-La Roche approach. |
| Mount Mettur Pharmaceuticals (P) Ltd. v. Dr. A. Wander, AIR 1977 Madras 105 |
Indian authority concerning trademarks in the pharmaceutical field. |
Cited by defendant's counsel; the court noted it formed part of the consistent jurisprudence supporting evaluation of deceptive similarity in context of pharmaceutical goods. |
| Chemical Industrial and Pharmaceutical Laboratories Ltd. v. A. Wulfing & another, (1979) 3 IPLR 193 (Bom. HC) |
Bombay High Court decision on trademarks in pharmaceuticals; cited to illustrate the approach in pharmaceutical cases. |
Referred to by defendant's counsel; the court recorded this as one of several decisions consistent with the Hoffmann-La Roche test and applied that reasoning. |
| Kemp & Co. Ltd. v. Cadilla Laboratories Private Limited |
Cited by the plaintiff; in that case the court granted a temporary injunction where there was very high (99%) phonetic similarity between "Campicillin" and "Kempsillin." |
The court considered this authority but distinguished it on facts, noting that the level of phonetic similarity in Kemp is not present between "Reclor" and "Curechlor." |
| Standard Pharmaceuticals Limited v. U.P. Drug Pvt. Ltd., 1980 IPLR 117 |
Authority where "Winotone" was held to infringe "Vintone" for medicinal preparations; the products there were tonics and not Schedule H drugs. |
The court distinguished this case on the ground that the products there were tonics (not Schedule H drugs) and thus the circumstances differed from the present Schedule H pharmaceutical context. |
Court's Reasoning and Analysis
The court's analysis proceeded by applying the principle, drawn from F. Hoffiman-La Roche and related authorities, that deceptive similarity must be assessed in light of the class of goods to which the trademarks relate. The judge emphasized that medicinal and pharmaceutical preparations, especially those that are dispensed on prescription, present a distinct factual matrix for the assessment of confusion.
First, the court compared the marks visually and phonetically. It found that the marks are "obviously not similar visually" because the defendant's mark begins with "Cu" preceding the entirety of "Reclor" and includes an added "h" after the "c." Phonetically the court also found "a distinct dissimilarity" between "Reclor" and "Curechlor" (the opinion records the defendant's mark as "Curechlor" and the plaintiff's mark as "Reclor"). The court expressly rejected the plaintiff's submission that the "cu" might be spoken feebly or be inaudible and thereby cause confusion.
Second, the court evaluated the context of sale and regulatory safeguards: Chloramphenicol is a Schedule H drug. The court cited sub-rule (9)(a) of Rule 65 and sub-rule (11) of Rule 65 of the Drugs and Cosmetics Rules, 1945, which restrict sale of Schedule H drugs to prescription-only distribution and impose requirements on dispensing chemists (including qualifications). The court reasoned that these restrictions and safeguards mean that chemists—who must be qualified and who dispense only on prescription—are unlikely to be confused by the defendant's trademark when selling the plaintiff's product.
Third, the court considered evidence of bona fides and user practices: the defendant's trading name Curewel and its price list (effective July 1, 1985) show multiple product names beginning with "Cure," suggesting that "Cure" is a customary prefix in the defendant's branding; the defendant's explanation was that "Cure" came from the trading style and "chlor" from the product (Chloramphenicol). The court noted that the plaintiff had not alleged or placed material on record demonstrating dishonest adoption by the defendant.
Fourth, the court observed that the plaintiff did not place any material on record to prima facie show that any particular person (ordinary customer or chemist) was actually misled into taking the defendant's product as that of the plaintiff. The two cash memos produced by the plaintiff showed the presence of prescribing doctors' names and indicated sale on prescription, reinforcing the court's view about prescription-based dispensing.
On the cumulative basis of (a) lack of visual and phonetic similarity, (b) regulatory and dispensing safeguards for Schedule H drugs, (c) absence of evidence of dishonest adoption, and (d) lack of prima facie evidence of confusion, the court concluded that the plaintiff did not make out a prima facie case nor show a strong likelihood of ultimate success necessary for interim relief.
Holding and Implications
I.A. dismissed.
Direct consequences: the interlocutory application for a temporary injunction was dismissed; the suit itself remained on the court's roll (directions were given for admission/denial of documents before the Deputy Registrar and for framing of issues on a later date). The opinion did not articulate any broader legal principle or seek to lay down a new precedent beyond applying the existing authorities to the facts; therefore, no new precedent was announced by this order and its immediate effect was to refuse interim relief to the plaintiff.
Show full summary ...